Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
作者： C G Moertel , T R Fleming , J S Macdonald , D G Haller , J A Laurie
DOI: 10.1200/JCO.1995.13.12.2936
关键词:
摘要: PURPOSETo determine the effectiveness of fluorouracil plus levamisole administered postoperatively to patients with resected stage II (Dukes' B2) colon cancer.PATIENTS AND METHODSThis randomized controlled clinical trial (INT-0035) was performed by National Cancer Institute-sponsored cancer trials cooperative groups. Patients were assigned observation only or (450 mg/m2 intravenously [IV] daily for 5 days and, beginning at 28 days, weekly 48 weeks) (50 mg orally three times 3 repeated every 2 weeks 1 year). recurrence, survival, and treatment side effects assessed.RESULTSThree hundred eighteen eligible analyzed a median follow-up time 7 years. Fluorouracil reduced recurrence rate 31%, although this trend not statistically significant (P = .10). A total 87 died: 43 on 44 levamisole. Disparity between o...
sci-hub.se 参考文章(10)
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
N Wolmark, H Rockette, B Fisher, D L Wickerham, C Redmond, E R Fisher, J Jones, E P Mamounas, L Ore, N J Petrelli, The Benefit of Leucovorin-Modulated Fluorouracil as Postoperative Adjuvant Therapy for Primary Colon Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-03 Journal of Clinical Oncology. ,vol. 11, pp. 1879- 1887 ,(1993) , 10.1200/JCO.1993.11.10.1879
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Thomas E. Witzig, Charles L. Loprinzi, Nick J. Gonchoroff, Herbert M. Reiman, Steven S. Cha, H. Sam Wieand, Jerry A. Katzmann, J. Kevin Paulsen, Charles G. Moertel, DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer. ,vol. 68, pp. 879- 888 ,(1991) , 10.1002/1097-0142(19910815)68:4<879::AID-CNCR2820680434>3.0.CO;2-4
Jin Jen, Hoguen Kim, Steven Piantadosi, Zong-Fan Liu, Roy C Levitt, Pertti Sistonen, Kenneth W Kinzler, Bert Vogelstein, Stanley R Hamilton, None, Allelic Loss of Chromosome 18q and Prognosis in Colorectal Cancer New England Journal of Medicine. ,vol. 331, pp. 213- 221 ,(1994) , 10.1056/NEJM199407283310401
RT Chlebowski, L Lillington, JS Nystrom, J Sayre, Late mortality and levamisole adjuvant therapy in colorectal cancer. British Journal of Cancer. ,vol. 69, pp. 1094- 1097 ,(1994) , 10.1038/BJC.1994.214
R. Pichlmayr, H. Pichlmaier, W. Schmiegel, P. Buggisch, K. Höffken, H. Hirche, Rudolf Pichimayr, Peter Buggisch, Jens Witte, German Cancer Aid –A Study Group, G. Riethmüller, R. Gruber, E. Schneider-Gädicke, G. Schlimok, J. Witte, R. Raab, Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma The Lancet. ,vol. 343, pp. 1177- 1183 ,(1994) , 10.1016/S0140-6736(94)92398-1
J A Laurie, C G Moertel, T R Fleming, H S Wieand, J E Leigh, J Rubin, G W McCormack, J B Gerstner, J E Krook, J Malliard, Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. Journal of Clinical Oncology. ,vol. 7, pp. 1447- 1456 ,(1989) , 10.1200/JCO.1989.7.10.1447
Alfred M. Cohen, Surgical considerations in patients with cancer of the colon and rectum. Seminars in Oncology. ,vol. 18, pp. 381- 387 ,(1991) , 10.5555/URI:PII:0093775491900955
P Piedbois, M Buyse, Y Rustum, D Machover, C Erlichman, RW Carlson, F Valone, R Labianca, JH Doroshow, N Petrelli, Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate by the advanced colorectal cancer meta-analysis project Journal of Clinical Oncology. ,vol. 10, pp. 896- 903 ,(1992) , 10.1200/JCO.1992.10.6.896